NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.
Iqvia will collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulatory actions.
This collaboration will allow NRx to access Iqvia's domain experience with COVID-19, our unparalleled data assets, and analytics to support potential emergency use authorization of Zyesami.
Iqvia will work closely with NRx to support key activities required for EUA activation, including the pharmacovigilance and medical information programs.
NRx Pharmaceuticals (NASDAQ-GS: NRXP) draws upon more than 300 combined years of scientific and drug-development experience to bring improved health to patients.
Its investigational product, Zyesami (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority part of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense.
Iqvia (NYSE: IQV) is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
With approximately 74,000 employees, Iqvia conducts operations in more than 100 countries.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients